Ruvonoflast aims to address the restricted blood flow and numbness associated with plaque buildup in arteries. According to the company, the drug candidate has completed five human clinical trials, demonstrating a favorable safety profile and the ability to achieve broad tissue distribution, including reach into the central nervous system. Rezera prioritized this indication due to the substantial unmet medical need within a large patient population suffering from the condition.
In section Market Quotes
Biotech Startup Rezera Targets Nasdaq Listing
Peripheral artery disease has become the primary focus for Rezera as the biotechnology startup formally filed for an initial public offering with the U.S. Securities and Exchange Commission. The company intends to leverage the proceeds to advance its lead drug candidate, ruvonoflast, while seeking a listing on the Nasdaq under the ticker RZRA.
While the filing marks a significant step toward public markets, the company has not yet disclosed the anticipated size of the offering or a projected price range for its shares. Investors are awaiting further details on the valuation and the specific timeline for the Nasdaq debut.
Comments (0)
No comments yet. Be the first!